Compare EPAC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | IMCR |
|---|---|---|
| Founded | 1910 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | EPAC | IMCR |
|---|---|---|
| Price | $40.10 | $35.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $50.50 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 369.8K | 338.1K |
| Earning Date | 12-17-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 8.66 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $616,899,000.00 | $379,590,000.00 |
| Revenue This Year | $6.18 | $32.31 |
| Revenue Next Year | $5.58 | $10.50 |
| P/E Ratio | $23.84 | ★ N/A |
| Revenue Growth | 4.65 | ★ 28.11 |
| 52 Week Low | $36.51 | $23.15 |
| 52 Week High | $49.40 | $40.72 |
| Indicator | EPAC | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.90 | 46.22 |
| Support Level | $36.80 | $35.35 |
| Resistance Level | $41.73 | $40.71 |
| Average True Range (ATR) | 0.99 | 1.91 |
| MACD | 0.45 | -0.48 |
| Stochastic Oscillator | 68.05 | 8.76 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.